PROVIDER HEALTH ADVISORY

Date: December 1, 2022
Contact: Rick Rosen, MD, MPH, 805-781-5500, frosen@co.slo.ca.us

Bebtelovimab No Longer Authorized for Use in the United States
Paxlovid remains first-line treatment option for COVID-19

The U.S. Food and Drug Administration (FDA) yesterday announced that bebtelovimab is no longer authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1., according to data included in the Health Care Provider Fact Sheet.

In California and nearby states, BQ variants now account for 57.7% of recent sequenced samples, similar to national levels.

Health care providers should use other approved or authorized products that are expected to retain activity against BQ.1 and BQ.1.1 as they choose appropriate treatment options for patients.

As a reminder: the first-line treatment option for COVID-19 remains Paxlovid. The second-line treatment option for COVID-19 is Remdesivir.

Updated FDA Fact Sheet for bebtelovimab: www.fda.gov/media/156152/download

Full FDA Announcement: www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region

Find local updates at SLOPublicHealth.org/COVID19.